UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
(Address of principal executive offices, including zip code)
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading |
Name of each exchange | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 8.01 | Other Events. |
Press Release
On March 3, 2022, Recursion Pharmaceuticals, Inc. issued a press release providing updated guidance on clinical trial starts. A copy of the press release is attached hereto as Exhibit 99.1.
Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits
Exhibit No. |
Description | |
99.1 | Press Release, dated March 3, 2022. | |
104 | Cover Page Interactive Data File (formatted as Inline XBRL) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
RECURSION PHARMACEUTICALS, INC. | ||||||
Date: March 3, 2022 |
By: | /S/ Christopher Gibson | ||||
Name: Christopher Gibson Title: Chief Executive Officer |
Exhibit 99.1
Recursion Provides Updated Guidance on Clinical Trial Starts
SALT LAKE CITY, March 3, 2022 Recursion (NASDAQ: RXRX) today provided updated guidance on clinical trial starts:
| Recursions leadership team has decided that conducting a dose optimization study in a sheep efficacy model of Tay-Sachs disease is prudent and in the best interest of patients before enrolling infants in a Phase 2 trial of REC-3599 in the ultra-rare indication infantile GM2 gangliosidosis. This decision will delay the GM2 Phase 2 trial start by approximately 2 years. |
| Recursions Phase 2 trial of REC-994 in Cerebral Cavernous Malformation is on track and we expect to enroll the first patient in the coming weeks. |
| The Phase 2 portion of Recursions adaptive Phase 2/3 trial of REC-2282 in Neurofibromatosis Type 2 is on track to enroll in Q2. |
| Recursions Phase 2 trial of REC-4881 in Familial Adenomatous Polyposis is expected to enroll the first patient in either Q2 or potentially Q3, 2022 due to challenges with site opening presented by the Covid-19 Omicron variant. |
| Preparations for Recursions Phase 1 study of REC-3964 in recurrent C. difficile colitis are on track, and we expect to begin enrollment in the second half of 2022. |
About Recursion
Recursion is the clinical-stage biotechnology company industrializing drug discovery by decoding biology. Enabling its mission is the Recursion Operating System, a platform built across diverse technologies that continuously expands one of the worlds largest proprietary biological and chemical datasets, the Recursion Data Universe. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset the Recursion Map, a collection of hundreds of billions of searchable inferences across biology and chemistry unconstrained by human bias. By commanding massive experimental scale up to millions of wet lab experiments weekly and massive computational scale owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology and chemistry to advance the future of medicine.
The company is proudly headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Toronto, Montréal and the San Francisco Bay Area. Learn more at www.Recursion.com, or connect on Twitter and LinkedIn.
Media Contact
Media@Recursion.com
Investor Contact
Investor@Recursion.com
Forward-Looking Statements
This document contains information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995, including, without limitation, those regarding Recursions mission; early and late stage discovery, preclinical, and clinical programs; licenses and collaborations; prospective products and their potential future indications and market opportunities; Recursion OS and other technologies; expansion of facilities and expected uses; workforce growth; employee stock trading plans; business and financial plans and performance; and all other statements that are not historical facts. Forward-looking statements may or may not include identifying words such as plan, will, expect, anticipate, intend, believe, potential, continue, and similar terms. These statements are subject to known or unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements, including but not limited to: challenges inherent in pharmaceutical research and development, including the timing and results of preclinical and clinical programs, where the risk of failure is high and failure can occur at any stage prior to regulatory approval due to lack of sufficient efficacy, safety considerations, or other factors; our ability to leverage and enhance our drug discovery platform; our ability to obtain financing for development activities and other corporate purposes; the success of our collaboration activities; our ability to obtain regulatory approval of, and ultimately commercialize, drug candidates; the impact of the COVID-19 pandemic and force majeure events; our ability to obtain, maintain, and enforce intellectual property protections; cyberattacks or other disruptions to our technology systems; our ability to attract, motivate, and retain key employees and manage our growth; and other risks and uncertainties such as those described under the heading Risk Factors in our filings with the U.S. Securities and Exchange Commission, including our most recent Quarterly Report on Form 10-Q. All forward-looking statements are based on managements current estimates, projections, and assumptions, and Recursion undertakes no obligation to correct or update any such statements, whether as a result of new information, future developments, or otherwise, except to the extent required by applicable law.
Document and Entity Information |
Mar. 03, 2022 |
---|---|
Cover [Abstract] | |
Amendment Flag | false |
Entity Central Index Key | 0001601830 |
Document Type | 8-K |
Document Period End Date | Mar. 03, 2022 |
Entity Registrant Name | RECURSION PHARMACEUTICALS, INC. |
Entity Incorporation State Country Code | DE |
Entity File Number | 001-40323 |
Entity Tax Identification Number | 46-4099738 |
Entity Address, Address Line One | 41 S Rio Grande Street |
Entity Address, City or Town | Salt Lake City |
Entity Address, State or Province | UT |
Entity Address, Postal Zip Code | 84101 |
City Area Code | (385) |
Local Phone Number | 269-0203 |
Written Communications | false |
Soliciting Material | false |
Pre Commencement Tender Offer | false |
Pre Commencement Issuer Tender Offer | false |
Security 12b Title | Class A common stock, $0.00001 par value per share |
Trading Symbol | RXRX |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | true |
Entity Ex Transition Period | false |
-8?20$3;8T.P6BP^0"X99K>]9!:G